Research articles on peptide biology, tissue repair, growth hormone secretagogues, and investigational compounds.
A new randomized clinical trial has given Pep19 its most important human test yet. In adults with obesity, the oral peptide changed abdominal fat distribution and improved insulin-related markers without producing significant weight loss. The result points to a different metabolic strategy, but the study was small, short, and not enough to establish clinical effectiveness or safety.
New peer-reviewed zenagamtide phase 2 results update the former amycretin program with separate oral and once-weekly studies in adults with type 2 diabetes. The findings show glucose-lowering activity and primarily gastrointestinal adverse events, while a registered phase 3 obesity study is designed to compare weekly zenagamtide with semaglutide.
Counterfeit semaglutide and tirzepatide have shown up in the legitimate U.S. drug supply chain, in some cases laced with unapproved substances. Here’s exactly what to check before you trust a dose.
Every GLP-1 headline throws around a weight-loss percentage. Here’s how to actually read the trial behind it — phases, placebo adjustment, endpoints, and the tricks press releases use to make numbers look bigger than they are.
New to research peptides in 2026? Start here — a practical orientation covering what research peptides actually are, the current legal landscape, how to evaluate vendors, and where to go next.
The FDA has published 17 revised draft product-specific guidances for generic peptide drugs, including semaglutide and tirzepatide. The documents explain how future applicants may demonstrate quality, similarity, biological activity, and therapeutic equivalence without treating complex peptides like ordinary small-molecule generics.
Lipfendra, the brand name for enlicitide, is the first FDA-approved oral PCSK9 inhibitor. CORALreef trials found approximately 56% to 59% placebo-adjusted LDL-C reductions at Week 24, while cardiovascular-outcomes data are still pending.
In the phase 2 EMBRAZE trial, adults receiving tirzepatide plus apitegromab lost a similar amount of total weight as those receiving tirzepatide plus placebo, but retained substantially more lean mass. The result is an early proof of concept, not a treatment recommendation or evidence of long-term functional benefit.
Understanding the tolerability profiles reported in research studies is important context for evaluating peptide research. This overview covers what animal and early human studies have reported.
Growth hormone secretagogues and anabolic peptides are among the most-studied compounds in the performance research space. Here is what the published evidence actually shows.
